VolitionRX

VolitionRx Limited (NYSE:VNRX ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Cameron Reynolds - President & Chief Executive Officer Terig Hughes - Chief Financial Officer Andrew Retter - Chief Medical Officer Conference Call Participants Bruce Jackson - The Benchmark Company Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Investment Research Operator Good afternoon ladies and gentlemen and thank you for standing by. Welcome to VolitionRx Limited Fourth Quarter and Full Fiscal Year 2024 Earnings Conference Call.» Mehr auf seekingalpha.com

Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada , March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024.» Mehr auf prnewswire.com

Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized  for the early identification of subjects at high risk of cancer HENDERSON, Nev. , March 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025 (ELCC 2025).» Mehr auf prnewswire.com